Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
808 The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances responses to anti-PD-1 immunotherapy
Compose a Response to This Article
Other responses
No responses have been published for this article.
